Immuno-Oncology Panel Session

Kineticos recently tapped 3 industry veterans and Oncology experts to participate in a panel to discuss where we are today in terms of the Immuno-Oncology treatment landscape and what the future holds.  This third installment of the series discusses how biotechs can stand out amongst the myriad of drug developers seeking investment for their I/O programs.

Panel Members

• Chris Heery – Chief Medical Officer, Bavarian Nordic
• Jeff Kmetz – Former Chief Business Officer, Pulse Biosciences
• Alex Dusek – Vice President of Commercial Strategy, Erytech

Click here for a condensed and edited version of Part 3.

• Part 1 – Checkpoint Inhibitors and Beyond
• Part 2 – Paying for Outcomes and Only Outcomes
• Part 3 – Data is King